Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, United States.
Front Immunol. 2018 Oct 23;9:2446. doi: 10.3389/fimmu.2018.02446. eCollection 2018.
Sepsis is a leading cause of death worldwide. After initial trials modulating the hyperinflammatory phase of sepsis failed, generations of researchers have focused on evaluating hypo-inflammatory immune phenotypes. The main goal has been to develop prognostic biomarkers and therapies to reduce organ dysfunction, nosocomial infection, and death. The depressed host defense in sepsis has been characterized by broad cellular reprogramming including lymphocyte exhaustion, apoptosis, and depressed cytokine responses. Despite major advances in this field, our understanding of the dynamics of the septic host response and the balance of inflammatory and anti-inflammatory cellular programs remains limited. This review aims to summarize the epidemiology of nosocomial infections and characteristic immune responses associated with sepsis, as well as immunostimulatory therapies currently under clinical investigation.
脓毒症是全球范围内主要的死亡原因。在最初尝试调节脓毒症的过度炎症期失败后,几代研究人员都专注于评估低炎症免疫表型。主要目标是开发预后生物标志物和疗法,以减少器官功能障碍、医院感染和死亡。脓毒症中宿主防御功能的抑制特征是广泛的细胞重编程,包括淋巴细胞耗竭、细胞凋亡和细胞因子反应抑制。尽管在这一领域取得了重大进展,但我们对脓毒症宿主反应的动态和炎症与抗炎细胞程序之间的平衡的理解仍然有限。本综述旨在总结与脓毒症相关的医院感染的流行病学和特征性免疫反应,以及目前正在临床研究中的免疫刺激治疗方法。